Publication | Open Access

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Breast OncologyOncologyWsg-adapt-hr+/her2− TrialPharmacologyBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentNeoadjuvant PartMedicineDose-dense Epirubicin